JUBILANT LIFE SCIENCES LIMITED - 530019 - Compliance Certificate For September 30, 2020
Compliance Certificate pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 JUBILANT LIFE SCIENCES LIMITED - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to the provisions of Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has issued duplicate share certificate to the following member as per the attachment. This is for your information and record. JUBILANT LIFE SCIENCES LIMITED - 530019 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we are enclosing a Confirmation Certificate for the quarter ended September 30, 2020 received from M/s Alankit Assignments Limited, Registrar and Share Transfer Agent of the Company. JUBILANT LIFE SCIENCES LIMITED - 530019 - Issuance Of Commercial Papers Of Rs. 90 Crore
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has issued Commercial Papers ('CPs') of Rs. 90 Crore on October 12, 2020. JUBILANT LIFE SCIENCES LIMITED - 530019 - Submission Of Trust Deed
Pursuant to Regulation 3(3) of the SEBI (Share Based Employee Benefits) Regulations, 2014, we enclose executed Trust Deed. JUBILANT LIFE SCIENCES LIMITED - 530019 - Issuance Of Commercial Papers Of Rs. 30 Crore
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has issued Commercial Papers ('CPs') of Rs. 30 Crore on October 9, 2020. JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Pursuant to SEBI Circular no.SEBI/HO/ISD/ISD/CIR/P/2020/135 dated July 23, 2020, we enclose Report under the Code of Conduct under the SEBI (Prohibition of Insider trading) Regulations, 2015. Please let us know if you need any other information in this regard. Thanking You, JUBILANT LIFE SCIENCES LIMITED - 530019 - Closure of Trading Window
Intimation regarding closure of Trading Window Pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company will be closed for 'Designated Persons' from Thursday, September 24, 2020 and the same shall remain closed till 48 hours after announcement of the financial results for the quarter ending September 30, 2020 to the Stock Exchanges. Accordingly, the Designated Persons have been intimated not to trade in the securities of the Company during the aforesaid period of closure of Trading Window. This is for information and record. JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor/ Analyst Meetings on September 22, 2020 Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company is organising a Conference Call with the Investor/ analysts on September 22, 2020. We enclose details of analyst conference calls scheduled for the same. We also enclose the presentation to be used during the Conference Call. We request you to take the same on record.
Saptagir Laboratories signs Remdesivir manufacturing deal with Jubilant Generics
Remdesivir is an experimental antiviral drug developed by Gilead Sciences, Inc. as a course of treatment for covid-19. Gilead entered into a non-exclusive licensing agreement with Jubilant Life Sciences for distribution to 127 countries.